UnknownNot Applicable

Relmacabtagene Autoleucel in Patients With LBCL

China200 participantsStarted 2022-12-28

Plain-language summary

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients with established r/r LBCL;
✓. Patients already treated with commercially available Relmacabtagene Autoleucel

What they're measuring

ORR

Timeframe: 6 months

Trial details

NCT IDNCT06142175

SponsorShanghai Ming Ju Biotechnology Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Medical JWCAR029, PhD

+86 21 50464201 JWCAR029Medical@jwtherapeutics.com

View on ClinicalTrials.gov More Large B-cell Lymphoma trials